Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.

Literature DB >> 17170728

Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.

A Curti, M Aluigi, S Pandolfi, E Ferri, A Isidori, V Salvestrini, I Durelli, A L Horenstein, F Fiore, M Massaia, M Piccioli, S A Pileri, E Zavatto, A D'Addio, M Baccarani, R M Lemoli.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2006 PMID： 17170728 DOI： 10.1038/sj.leu.2404485

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

44 in total

Review 1. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors: Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal: Blood Date: 2011-08-31 Impact factor: 22.113

2. Kynurenine and uric acid levels in chronic myeloid leukemia patients.

Authors: Vladimir Vonka; Zuzana Humlova; Hana Klamova; Lenka Kujovska-Krcmova; Martina Petrackova; Eva Hamsikova; Monika Krmencikova-Fliegl; Martina Duskova; Zdenek Roth
Journal: Oncoimmunology Date: 2015-03-25 Impact factor: 8.110

Review 3. Trial watch: IDO inhibitors in cancer therapy.

Authors: Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2014-12-15 Impact factor: 8.110

Review 4. Alterations of T-cell-mediated immunity in acute myeloid leukemia.

Authors: Zhuoyan Li; Mary Philip; P Brent Ferrell
Journal: Oncogene Date: 2020-03-03 Impact factor: 9.867

5. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.

Authors: Noura M El Kholy; Maha M Sallam; Manal B Ahmed; Reem M Sallam; Inas A Asfour; Jehad A Hammouda; Haidy Z Habib; Fatima Abu-Zahra
Journal: Med Oncol Date: 2010-03-19 Impact factor: 3.064

Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.

Review 1. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

2. Kynurenine and uric acid levels in chronic myeloid leukemia patients.

Review 3. Trial watch: IDO inhibitors in cancer therapy.

Review 4. Alterations of T-cell-mediated immunity in acute myeloid leukemia.

5. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.

Review 6. IDO-expressing regulatory dendritic cells in cancer and chronic infection.

7. Potential role of indoleamine 2,3-dioxygenase in primary biliary cirrhosis.

8. Molecular cloning and characterization of porcine indoleamine 2, 3-dioxygenase and its expression in various tissues.

9. Increased TTS expression in patients with rheumatoid arthritis.

10. Increased TTS abrogates IDO-mediated CD4(+) T cells suppression in patients with Graves' disease.